Does spirometry predict dyspnoea in advanced cancer?

Area of Science:

• Pulmonology
• Oncology
• Respiratory Medicine

Background:

• Dyspnoea is a common and distressing symptom in advanced cancer patients.
• Objective measures of respiratory function are crucial for understanding and managing dyspnoea.
• The relationship between subjective dyspnoea and objective lung function in this population requires further investigation.

Purpose of the Study:

• To compare subjective dyspnoea assessments with objective spirometric indices in advanced cancer patients.
• To determine the correlation between visual analogue scale (VAS) dyspnoea scores and spirometry results.
• To characterize respiratory function impairment in this patient group.

Main Methods:

• Investigated 155 advanced cancer patients, assessing dyspnoea using 24-hour visual analogue scales (VASMe 24).
• Performed spirometry, including post-salbutamol measurements, on 108 patients to evaluate respiratory function.
• Calculated predicted spirometry values using measured height and weight for 84 patients.

Main Results:

• 71% of patients experienced dyspnoea, and 70% showed impaired respiratory function via spirometry.
• Spirometry results (FEV1, FVC) were frequently lower than predicted, with a mean FEV1/FVC ratio of 0.65, indicating obstructive impairment.
• Correlations between VAS dyspnoea scores and spirometric indices were low, suggesting spirometry cannot reliably measure subjective breathlessness.

Conclusions:

• Objective spirometry in advanced cancer patients frequently reveals impaired and obstructive respiratory function.
• Subjective dyspnoea, as measured by VAS, is poorly correlated with objective spirometric measures.
• Spirometry is not a reliable surrogate for assessing patient-reported dyspnoea in advanced cancer.